Stifel Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has maintained a Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) but has reduced the price target from $11 to $10.

November 14, 2023 | 5:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on ALX Oncology Holdings but lowers the price target from $11 to $10.
While the reduction in price target could suggest a slightly less optimistic outlook on the stock's valuation, the maintenance of a Buy rating indicates that the analyst still sees upside potential. This mixed signal may lead to a neutral short-term impact on the stock price as investors digest both the positive and negative aspects of the update.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100